There are no active trials at this time. Please check back at a later date, or call the office to have your information added to a waiting list. Please contact Marsha at (971) 220 2208 for additional information about the study.
Asthma is a chronic disease of the lungs that narrows and inflames the airways, making it difficult to breathe. This condition affects individuals of all ages, but most often begins in childhood. Because asthma can have a number of different causes and may be confused with other conditions that affect the airways, the first step to improving your symptoms is receiving an accurate diagnosis.
At Columbia Asthma & Allergy Clinic, we specialize in the treatment of allergy and asthma-related conditions.
There are no active trials at this time. Please check back at a later date, or call the office to have your information added to a waiting list.
Please contact Marsha at (971) 220 2208 for additional information about the study.
Medical Condition: Asthma
Purpose of Study: To evaluate the safety and effectiveness of dupilumab in patients with persistent asthma
- 12 years of age and older
- Diagnosed with asthma for at least 12 months
Treatment with an inhaled corticosteroid and a second controller medication for at least 3 months. Examples of inhaled corticosteroids include, but are not limited to Advair Diskus® or Advair HFA®, Symbicort®, Dulera®, Flovent Diskus® or Flovent HFA®, and Pulmicort®. Examples of secondary controller medication includes, but are not limited to Serevent Diskus®, Foradil®, Singulair®, Accolate®, and Theophylline.
At least 1 asthma flare-up in the past 12 months requiring either treatment with a systemic corticosteroid OR emergency medical care or hospitalization. Examples of systemic corticosteroids include, but are not limited to prednisone, prednisolone, methylprednisolone, and dexamethasone.
Compensation: There is no cost to you to take part in this study. Qualified participants may receive all study related care and study medication at no cost. YOU WILL BE COMPENSATED FOR YOUR TIME AND TRAVEL.